Archives
-
Human Intestinal Organoids with Tunable Cell Fate
2026-10-01
The reference study develops a human small intestinal organoid system that maintains strong proliferation while expanding epithelial cell diversity under a unified culture strategy. By combining stemness-enhancing pathway modulation with reversible and lineage-directed fate control, the work offers a practical framework for scalable organoid research without recreating complex spatial signaling gradients.
-
AM 281 in CB1 Receptor Signaling Research
2026-10-01
AM 281 gives neuropharmacology researchers a selective way to interrogate CB1-dependent regulation of astrocytic GLT-1, glutamate excitotoxicity, and cognition. This workflow translates traumatic brain injury findings into practical assay design, controls, timing strategies, and troubleshooting decisions.
-
Caspase 3/7, Autophagy, and DNA Damage Responses
2026-09-30
A 2025 PLOS Biology study identifies CASP3 and CASP7 as active regulators of cytoprotective autophagy and DNA damage signaling during non-lethal stress in human breast cancer cells. Its rescue experiments and synthetic-lethality results connect caspase-dependent PARP1 modulation with H2AX phosphorylation and suggest a framework for studying stress adaptation beyond apoptosis.
-
CHIR 99021: Engineering Stem Cell Fate
2026-09-30
A strategic guide to using CHIR 99021 trihydrochloride as a tunable GSK-3 inhibitor in organoid engineering, stem cell research, insulin signaling, and preclinical metabolic disease models.
-
Novobiocin Sodium: Assay Workflows & Use Cases
2026-09-29
Novobiocin Sodium combines a defined DNA gyrase-directed mechanism with practical solubility options for bacterial, cell-based, DNA damage, and antiparasitic research. This guide translates the Toxoplasma gondii evidence into assay design, workflow controls, and troubleshooting decisions without overstating mechanism or translational maturity.
-
Bacitracin B1670: Protocol and QC Guide
2026-09-29
Bacitracin B1670 is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis. This guide covers solvent selection, storage, assay controls, and interpretation limits; the material is for scientific research only and is not intended for diagnostic, clinical, or medical use.
-
ERADECs: Hijacking ERAD to Degrade Membrane Proteins
2026-09-28
Song and colleagues establish ERAD-engaging chimeras (ERADECs), a small-molecule platform that redirects transmembrane proteins to ER-associated degradation through the E3 ligase SYVN1. Desonide-based ERADECs produce highly effective PD-L1 depletion, enhance tumor suppression in vivo, and extend ERAD-hijacking beyond one membrane target.
-
USP36–Snail1 Signaling Under Ribotoxic Stress
2026-09-28
The study identifies a JNK–HSF1–USP36 pathway that stabilizes nucleolar Snail1 when ribosomes are stressed, helping cancer cells sustain ribosome biogenesis and survive. It also offers a mechanistic explanation for why homoharringtonine can be less effective in solid tumors than in leukemia and supports testing pathway inhibition alongside ribosome-targeting treatment.
-
Norepinephrine Bitartrate: Measuring Response, Not Tone
2026-09-27
Norepinephrine bitartrate is more than an adrenergic stimulus: its effects must be interpreted against vascular tone, heart rate, and exposure. A 2025 septic-shock analysis offers a useful framework for designing more informative cardiovascular experiments—without treating a clinical association as a preclinical dosing rule.
-
Self-Adaptive Nanocarriers for Pancreatic Cancer
2026-09-26
A 2025 ACS Nano study describes a pH- and reactive oxygen species-responsive nanocarrier designed to expose an arginine surface in pancreatic tumors, promote extracellular-matrix remodeling, and improve camptothecin delivery. Its findings connect tumor penetration with a proposed mitochondrial and microvesicle mechanism, while leaving important questions about safety, mechanism specificity, and clinical translation.
-
AAPH Workflows for Lipid Oxidation Assays
2026-09-25
Use AAPH to create a controllable, water-compatible peroxyl-radical challenge for erythrocyte hemolysis and lipid oxidation studies. This guide outlines practical pilot workflows and explains how to use AAPH alongside—rather than as a substitute for—mechanistic ferroptosis experiments informed by recent PRDX6–GPX4 research.
-
Ciclesonide Workflows for Airway Inflammation Research
2026-09-25
Ciclesonide offers a practical model for studying local prodrug activation and glucocorticoid responses in airway cells, with a measurable conversion benchmark to guide assay design. This workflow also places recent ERAD-hijacking research in context—without confusing its desonide-based technology with ciclesonide pharmacology.
-
DDM Workflows for Membrane Protein Cryo-EM
2026-09-24
Use n-Dodecyl-β-D-maltoside (DDM) to screen gentle solubilization and stabilization conditions for membrane-protein purification, functional assays, and structural studies. A practical workflow connects detergent optimization to the conformational heterogeneity revealed in full-length αvβ3 integrin—without assuming the reference study used DDM.
-
LIRP Enables Light-Controlled Therapeutic Translation
2026-09-24
The study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that suppresses translation in darkness and permits transgene expression under blue or ambient light. In mouse models, LIRP-regulated AAV gene switches enabled light-responsive control of obesity-related and retinal therapies, while highlighting the need to establish safety, light-delivery, and tissue-specific performance in further studies.
-
Eicosapentaenoic Acid (EPA): Mechanisms & Benchmarks
2026-09-23
Eicosapentaenoic Acid (EPA) is an omega-3 polyunsaturated fatty acid studied for lipid-lowering and anti-inflammatory effects. Product-reported benchmarks include membrane-related mechanisms and concentration-dependent in vitro effects, but they do not establish clinical efficacy or an immune-adjuvant effect.